

## Tyenne will be preferred tocilizumab biosimilar product for most commercial members, starting June 1

Blue Cross Blue Shield of Michigan and Blue Care Network will change how we manage Actemra® and Actemra® biosimilar products, starting June 1, 2025. This change will affect most Blue Cross and BCN commercial members under pharmacy and medical benefits.

### How this will affect members under pharmacy benefits

Actemra® (tocilizumab) subcutaneous, or SC, injection will no longer be covered for all commercial fully insured and self-funded groups using the Custom, Custom Select and Clinical drug lists. Tyenne® (tocilizumab-aazg) will be the preferred (tocilizumab) biosimilar product.

Authorizations for Actemra will remain in effect until May 31, 2025. If members decide to use Actemra on or after June 1, they'll be responsible for the full cost. New authorizations for Tyenne will be approved June 1, 2025, and active through May 31, 2026, so members can continue therapy without interruption.

Members on a plan using the Preferred Drug List are excluded from this change. This change doesn't apply to Medicare Advantage groups or members.

### Filling the prescription

We'll only pay for Tyenne when filled through Walgreens Specialty Pharmacy, an independent company that provides specialty pharmacy services to Blue Cross and BCN.

However, some members may be currently filling their Actemra prescriptions at the Michigan Medicine Specialty Pharmacy. We'll pay for Tyenne when filled at that pharmacy to allow those members to continue receiving this medication there.

If members are currently filling Actemra through Walgreens Specialty Pharmacy:

- Walgreens Specialty Pharmacy will obtain new prescriptions for Tyenne from their doctor, if needed.
- Walgreens Specialty Pharmacy will fill prescriptions with Tyenne on or after June 1.

If members are currently filling their prescriptions through pharmacies other than those mentioned above:

- Walgreens Specialty Pharmacy will send a welcome letter.
- A representative from Walgreens Specialty Pharmacy will be calling members to set up profiles.
- Walgreens Specialty Pharmacy will obtain new prescriptions for Tyenne from their doctor.

Prescribers can send a new prescription for Tyenne by one of the following methods:

Pharmacy	Methods
Walgreens Specialty Pharmacy	<ul style="list-style-type: none"> <li>Fax: 1-866-515-1356</li> <li>E-prescribing name: Walgreens Specialty Pharmacy – MICHIGAN</li> <li>Contact number: 1-866-515-1355</li> </ul>
Michigan Medicine Specialty Pharmacy	<ul style="list-style-type: none"> <li>Prescriber fax: 734-232-3408</li> <li>E-prescribing name: UM SPECIALTY HOME DELIVERY PHARMACY</li> <li>Address: 7300 West Joy Road Dexter, MI 48130</li> <li>Contact number: 1-855-276-3002</li> </ul>

**How this will affect members under medical benefits**

For dates of service on or after June 1, 2025, Tyenne® IV and SC (tocilizumab-aazg), HCPCS code Q5135, will be the preferred tocilizumab biosimilar product.

The nonpreferred tocilizumab products are Tofidence™ IV (intravenous), Avtozma® IV and SC and Actemra® IV and SC.

For members who have active authorizations for a nonpreferred tocilizumab product:

- These members are authorized to continue their current therapy through May 31, 2025.
- We’re issuing authorizations for Tyenne from June 1, 2025, to May 31, 2026, to avoid any interruptions in care.

To determine whether a group participates in the prior authorization program, see the [SpecialtyPharmacy Prior Authorization Master Opt-in/out Group list](#).

**How to submit prior authorization requests**

- For a self-administered (tocilizumab) product (covered under pharmacy benefits), submit the request using an electronic prior authorization, or ePA, tool such as CoverMyMeds® or Surescripts®.
- For an (tocilizumab) IV or SC product that requires administration by a health care provider (covered under medical benefits), submit the request through the NovoLogix® online tool.

[Subscribe](#) to Provider Alerts Weekly, a weekly email with a list of links to the previous week's provider alerts.

NovoLogix® is an independent company that provides an online prescription drug prior authorization tool for Blue Cross Blue Shield of Michigan and Blue Care Network.

Walgreens Specialty Pharmacy is an independent company that provides specialty pharmacy services covered under the pharmacy benefit for various Blue Cross Blue Shield of Michigan and Blue Care Network members with commercial plans.